Carra, S.; Gaudenzi, G.; Dicitore, A.; Saronni, D.; Cantone, M.C.; Plebani, A.; Ghilardi, A.; Borghi, M.O.; Hofland, L.J.; Persani, L.;
et al. Vandetanib versus Cabozantinib in Medullary Thyroid Carcinoma: A Focus on Anti-Angiogenic Effects in Zebrafish Model. Int. J. Mol. Sci. 2021, 22, 3031.
https://doi.org/10.3390/ijms22063031
AMA Style
Carra S, Gaudenzi G, Dicitore A, Saronni D, Cantone MC, Plebani A, Ghilardi A, Borghi MO, Hofland LJ, Persani L,
et al. Vandetanib versus Cabozantinib in Medullary Thyroid Carcinoma: A Focus on Anti-Angiogenic Effects in Zebrafish Model. International Journal of Molecular Sciences. 2021; 22(6):3031.
https://doi.org/10.3390/ijms22063031
Chicago/Turabian Style
Carra, Silvia, Germano Gaudenzi, Alessandra Dicitore, Davide Saronni, Maria Celeste Cantone, Alice Plebani, Anna Ghilardi, Maria Orietta Borghi, Leo J. Hofland, Luca Persani,
and et al. 2021. "Vandetanib versus Cabozantinib in Medullary Thyroid Carcinoma: A Focus on Anti-Angiogenic Effects in Zebrafish Model" International Journal of Molecular Sciences 22, no. 6: 3031.
https://doi.org/10.3390/ijms22063031
APA Style
Carra, S., Gaudenzi, G., Dicitore, A., Saronni, D., Cantone, M. C., Plebani, A., Ghilardi, A., Borghi, M. O., Hofland, L. J., Persani, L., & Vitale, G.
(2021). Vandetanib versus Cabozantinib in Medullary Thyroid Carcinoma: A Focus on Anti-Angiogenic Effects in Zebrafish Model. International Journal of Molecular Sciences, 22(6), 3031.
https://doi.org/10.3390/ijms22063031